vs
Side-by-side financial comparison of JOINT Corp (JYNT) and Sunshine Biopharma Inc. (SBFM). Click either name above to swap in a different company.
JOINT Corp is the larger business by last-quarter revenue ($15.2M vs $8.6M, roughly 1.8× Sunshine Biopharma Inc.). JOINT Corp runs the higher net margin — 6.5% vs -25.0%, a 31.5% gap on every dollar of revenue. On growth, JOINT Corp posted the faster year-over-year revenue change (3.1% vs -10.6%). JOINT Corp produced more free cash flow last quarter ($334.7K vs $-1.6M). Over the past eight quarters, Sunshine Biopharma Inc.'s revenue compounded faster (6.6% CAGR vs -28.6%).
The Joint Corp is a leading operator and franchisor of chiropractic care clinics primarily serving the U.S. market. It offers accessible, affordable routine chiropractic services, membership-based care plans, and caters to consumers seeking non-invasive musculoskeletal pain management and wellness support.
Sunshine Biopharma Inc. is a clinical-stage biopharmaceutical company focused on researching, developing and commercializing innovative therapies for oncology, neurodegenerative disorders and infectious diseases. It targets unmet medical needs across global markets, with a pipeline of targeted therapeutic candidates designed to improve patient treatment outcomes.
JYNT vs SBFM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.2M | $8.6M |
| Net Profit | $991.1K | $-2.1M |
| Gross Margin | 81.4% | 35.3% |
| Operating Margin | 4.9% | -20.9% |
| Net Margin | 6.5% | -25.0% |
| Revenue YoY | 3.1% | -10.6% |
| Net Profit YoY | 5510.5% | 0.8% |
| EPS (diluted) | $0.06 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.2M | $8.6M | ||
| Q3 25 | $13.4M | $9.4M | ||
| Q2 25 | $13.3M | $9.4M | ||
| Q1 25 | $13.1M | $8.9M | ||
| Q4 24 | $14.7M | $9.6M | ||
| Q3 24 | $30.2M | $8.4M | ||
| Q2 24 | $30.3M | $9.3M | ||
| Q1 24 | $29.7M | $7.5M |
| Q4 25 | $991.1K | $-2.1M | ||
| Q3 25 | $855.0K | $-883.8K | ||
| Q2 25 | $93.4K | $-1.8M | ||
| Q1 25 | $967.8K | $-1.2M | ||
| Q4 24 | $17.7K | $-2.2M | ||
| Q3 24 | $-3.2M | $-1.2M | ||
| Q2 24 | $-3.6M | $-494.3K | ||
| Q1 24 | $947.0K | $-1.3M |
| Q4 25 | 81.4% | 35.3% | ||
| Q3 25 | 80.1% | 32.6% | ||
| Q2 25 | 79.1% | 36.4% | ||
| Q1 25 | 77.3% | 30.7% | ||
| Q4 24 | 78.4% | 32.2% | ||
| Q3 24 | 90.7% | 34.0% | ||
| Q2 24 | 90.7% | 25.3% | ||
| Q1 24 | 90.9% | 31.2% |
| Q4 25 | 4.9% | -20.9% | ||
| Q3 25 | 1.2% | -11.5% | ||
| Q2 25 | -8.6% | -21.8% | ||
| Q1 25 | -5.2% | -14.6% | ||
| Q4 24 | 5.5% | -21.7% | ||
| Q3 24 | -1.6% | -13.1% | ||
| Q2 24 | -5.9% | -13.6% | ||
| Q1 24 | -1.4% | -17.9% |
| Q4 25 | 6.5% | -25.0% | ||
| Q3 25 | 6.4% | -9.4% | ||
| Q2 25 | 0.7% | -18.8% | ||
| Q1 25 | 7.4% | -13.3% | ||
| Q4 24 | 0.1% | -22.5% | ||
| Q3 24 | -10.5% | -14.2% | ||
| Q2 24 | -11.9% | -5.3% | ||
| Q1 24 | 3.2% | -17.0% |
| Q4 25 | $0.06 | — | ||
| Q3 25 | $0.06 | $-0.54 | ||
| Q2 25 | $0.01 | $-0.82 | ||
| Q1 25 | $0.06 | $-0.44 | ||
| Q4 24 | $0.01 | $49.77 | ||
| Q3 24 | $-0.21 | $-11.61 | ||
| Q2 24 | $-0.24 | $-43.48 | ||
| Q1 24 | $0.06 | $-2.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $23.6M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $15.1M | $23.0M |
| Total Assets | $61.0M | $30.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $23.6M | — | ||
| Q3 25 | $29.7M | — | ||
| Q2 25 | $29.8M | — | ||
| Q1 25 | $21.9M | — | ||
| Q4 24 | $25.1M | — | ||
| Q3 24 | $20.7M | — | ||
| Q2 24 | $17.5M | — | ||
| Q1 24 | $18.7M | — |
| Q4 25 | $15.1M | $23.0M | ||
| Q3 25 | $22.7M | $24.2M | ||
| Q2 25 | $23.2M | $25.7M | ||
| Q1 25 | $22.8M | $22.7M | ||
| Q4 24 | $20.7M | $23.5M | ||
| Q3 24 | $20.5M | $25.0M | ||
| Q2 24 | $23.2M | $23.5M | ||
| Q1 24 | $26.2M | $24.8M |
| Q4 25 | $61.0M | $30.1M | ||
| Q3 25 | $69.4M | $31.5M | ||
| Q2 25 | $73.2M | $32.0M | ||
| Q1 25 | $80.1M | $29.2M | ||
| Q4 24 | $83.2M | $30.6M | ||
| Q3 24 | $79.6M | $30.1M | ||
| Q2 24 | $82.4M | $29.3M | ||
| Q1 24 | $85.7M | $31.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.8M | $-1.6M |
| Free Cash FlowOCF − Capex | $334.7K | $-1.6M |
| FCF MarginFCF / Revenue | 2.2% | -18.9% |
| Capex IntensityCapex / Revenue | 9.9% | 0.0% |
| Cash ConversionOCF / Net Profit | 1.86× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-1.9M | $-5.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.8M | $-1.6M | ||
| Q3 25 | $1.8M | $-727.8K | ||
| Q2 25 | $868.6K | $-1.3M | ||
| Q1 25 | $-3.7M | $-1.7M | ||
| Q4 24 | $9.4M | $-3.4M | ||
| Q3 24 | $3.4M | $-1.4M | ||
| Q2 24 | $-973.5K | $-4.6M | ||
| Q1 24 | $2.8M | $-3.2M |
| Q4 25 | $334.7K | $-1.6M | ||
| Q3 25 | $1.5M | $-735.8K | ||
| Q2 25 | $363.6K | $-1.4M | ||
| Q1 25 | $-4.0M | $-1.7M | ||
| Q4 24 | $8.2M | $-3.5M | ||
| Q3 24 | $3.2M | $-1.9M | ||
| Q2 24 | $-1.2M | $-5.6M | ||
| Q1 24 | $2.4M | $-3.2M |
| Q4 25 | 2.2% | -18.9% | ||
| Q3 25 | 10.9% | -7.8% | ||
| Q2 25 | 2.7% | -15.2% | ||
| Q1 25 | -30.8% | -19.3% | ||
| Q4 24 | 55.9% | -36.6% | ||
| Q3 24 | 10.6% | -22.2% | ||
| Q2 24 | -4.1% | -59.7% | ||
| Q1 24 | 8.1% | -43.1% |
| Q4 25 | 9.9% | 0.0% | ||
| Q3 25 | 2.4% | 0.1% | ||
| Q2 25 | 3.8% | 1.7% | ||
| Q1 25 | 2.5% | 0.1% | ||
| Q4 24 | 8.1% | 1.1% | ||
| Q3 24 | 0.8% | 6.1% | ||
| Q2 24 | 0.9% | 10.5% | ||
| Q1 24 | 1.3% | 0.8% |
| Q4 25 | 1.86× | — | ||
| Q3 25 | 2.07× | — | ||
| Q2 25 | 9.30× | — | ||
| Q1 25 | -3.82× | — | ||
| Q4 24 | 532.98× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 2.97× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JYNT
| Transferred At Point In Time | $12.8M | 84% |
| Transferred Over Time | $2.4M | 16% |
SBFM
Segment breakdown not available.
